Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Of India Plans To Launch Actos Generic In U.S. In 2012

This article was originally published in PharmAsia News

Executive Summary

India's Ranbaxy Laboratories said it expects to launch its generic version of Takeda Pharmaceutical's Actos (pioglitazone) diabetes drug in the United States in 2012

You may also be interested in...



Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies

Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts. 

Spring Shopping: Ping An Bets On Shionogi, TCMs In Coronavirus Aftermath

China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.

EU Scientific Committee Affirms Safety Of Anti-Dandruff Zinc Pyrithione Under Threat Of Cosmetic Ban

The Scientific Committee for Consumer Safety upholds that zinc pyrithione is safe for use in rinse-off anti-dandruff hair products at levels up to 1%. In recent years, the cosmetics industry has pushed for a 2% ceiling on ZPT content in that capacity – with considerable inroads made. Where that proposal now stands vis-à-vis the ingredient’s pending CMR 1B classification and shifting political sands is uncertain.

UsernamePublicRestriction

Register

SC074282

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel